An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Expanded access is currently available for this treatment.
Verified July 2014 by Eisai Inc.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01240421
First received: October 1, 2010
Last updated: July 25, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is currently available for this treatment.
  Estimated Study Completion Date: March 2015
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)